Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Despina Tseneklidou-Stoeter"'
Autor:
Rolf Ljung, Anthony K. C. Chan, Heidi Glosli, Olubunmi Afonja, Bastian Becker, Despina Tseneklidou-Stoeter, Maria Elisa Mancuso, Sonata Saulyte-Trakymiene, Gili Kenet
Publikováno v:
Thrombosis and Haemostasis. 123:027-039
Introduction BAY 81–8973, a full-length recombinant factor VIII for hemophilia A treatment, has been extensively evaluated in previously treated patients in the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68aef4241eb0dc6c0d0234cea4eac6ad
https://doi.org/10.1055/s-0042-1757876
https://doi.org/10.1055/s-0042-1757876
Autor:
Maria Elisa Mancuso, Monika Maas Enriquez, Tina T. Biss, Despina Tseneklidou-Stoeter, MacGregor Steele, Maria Wang, Krista Fischer, Gili Kenet, Sanjay P Ahuja
Publikováno v:
Haemophilia
Introduction BAY 94‐9027 (damoctocog alfa pegol; an extended half‐life PEGylated recombinant factor VIII [FVIII]) demonstrated efficacy and safety in previously treated paediatric patients (PTPs) aged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e9eed4c3a7d7bf5b4093b2ac5e3ec6c
https://doi.org/10.1111/hae.14294
https://doi.org/10.1111/hae.14294
Autor:
Nikki Church, Despina Tseneklidou-Stoeter, Elena Santagostino, Shadan Lalezari, Johnny Mahlangu, Maria Fernanda Lopez Fernandez, Horst Beckmann
Publikováno v:
European Journal of Haematology
Objectives BAY 81‐8973 (Kovaltry®), a full‐length, unmodified, recombinant human factor VIII, provided excellent bleeding control for patients with haemophilia A in the pivotal 1‐year LEOPOLD I trial. The LEOPOLD I extension evaluated long‐t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9337a856d170e7aef97d873b01f72156
https://doi.org/10.1111/ejh.13402
https://doi.org/10.1111/ejh.13402
Autor:
Yongqiang Zhao, Despina Tseneklidou-Stoeter, Xuefeng Wang, Jing Sun, Renchi Yang, Nikki Church, Junde Wu, Depei Wu
Publikováno v:
Haemophilia
Introduction BAY 81-8973 (Kovaltry® ) is a full-length, unmodified recombinant human factor VIII approved in China for prophylaxis and on-demand treatment in patients with haemophilia A. Limited access to FVIII prophylaxis in China has historically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1f4d65d731bf8260c836bf5454a02a4
http://europepmc.org/articles/PMC6850381
http://europepmc.org/articles/PMC6850381
Autor:
Victor S. Blanchette, Bryce A. Kerlin, Rolf Ljung, Nikki Church, Valentina Uscatescu, Sonata Saulytė Trakymienė, L. Rusen, Despina Tseneklidou-Stoeter, Horst Beckmann, Gili Kenet
Publikováno v:
Thrombosis research, Kidlington : Pergamon-Elsevier Science Ltd., 2020, vol. 189, p. 96-101
Introduction BAY 81-8973 (Kovaltry®), a recombinant factor VIII (rFVIII) product, was efficacious and well tolerated in paediatric previously treated patients (PTPs) with severe haemophilia A for ≥50 exposure days (EDs) in the LEOPOLD Kids study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a711d7b9d4e4a7a7b1571ce30b248c3e
https://pubmed.ncbi.nlm.nih.gov/32197139
https://pubmed.ncbi.nlm.nih.gov/32197139
Autor:
Ho Jin Shin, Pål Andre Holme, Claude Negrier, Shadan Lalezari, Monika Maas Enriquez, Mark T. Reding, Pavani Chalasani, Despina Tseneklidou-Stoeter, Maria Wang, Ingrid Pabinger
Publikováno v:
Haemophilia
Introduction BAY 94-9027 is an extended-half-life, site-specifically PEGylated, B-domain-deleted recombinant factor VIII (FVIII). The PROTECT VIII main study demonstrated efficacy of bleed control using extended-interval prophylaxis with BAY 94-9027
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a9960da74036f47046472b269a2caa8
http://hdl.handle.net/10852/75885
http://hdl.handle.net/10852/75885
Publikováno v:
Biological Chemistry Hoppe-Seyler. 376:531-538
The primary structure of the carbohydrate chains of hemocyanin from the crayfish Astacus leptodactylus were investigated. The carbohydrate content is 0.2% (w/w) as referred to total hemocyanin content, resp. 1.8% as referred only to the one subunit w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d513dc4528c7d6e9a1aa52e92b5414d
https://doi.org/10.1515/bchm3.1995.376.9.531
https://doi.org/10.1515/bchm3.1995.376.9.531
Autor:
Despina Tseneklidou-Stoeter, Stefan Bruns, Steve Kitchen, Monika Maas Enriquez, Yvonne Katterle, H. Beckmann
Publikováno v:
Blood. 126:3539-3539
Background: BAY 81-8973 is a full-length unmodified recombinant factor VIII (rFVIII) in development for the treatment of hemophilia A. BAY 81-8973 has the same amino acid sequence as Bayer's sucrose-formulated rFVIII but is manufactured using the lat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b67f8807554ef2b3e4e412747467bfa
https://doi.org/10.1182/blood.v126.23.3539.3539
https://doi.org/10.1182/blood.v126.23.3539.3539